Cervical cancer
Conditions
Interventions
Tumor biopsy and peripheral blood sampling will be performed for research purposes before the initiation of radiotherapy as part of routine clinical diagnosis and during the radiation treatment period
Sponsors
National Institutes for Quantum Science and Technology
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Patients with cervical cancer scheduled to receive X-ray or carbon-ion radiotherapy Patients for whom tumor biopsy can be obtained before the initiation of radiotherapy Patients for whom additional tumor biopsy and peripheral blood sampling during the radiation treatment period for research purposes are feasible Female patients aged 20 years or older Patients who have provided written informed consent to participate in this study
Exclusion criteria
Exclusion criteria: Patients with severe immunosuppressive conditions Patients who are pregnant or possibly pregnant Patients judged by the treating physician to be inappropriate for participation in this study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Two-year local control rate, Two-year overall survival, and Changes in the immune microenvironment (immune cell composition, spatial distribution, gene expression, and TCR diversity) | — |
Secondary
| Measure | Time frame |
|---|---|
| Treatment-related adverse events, Correlation with clinical background and treatment course, and Exploratory evaluation of biomarker candidates | — |
Countries
Japan
Contacts
Public ContactTsuguhide TaTakeshima
National Institutes for Quantum Science and Technology Department of Charged Particle Therapy Research, QST Hospital
Outcome results
None listed